

Suxia Luo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9856910/publications.pdf>

Version: 2024-02-01

12
papers

1,527
citations

1162367

8
h-index

1199166

12
g-index

13
all docs

13
docs citations

13
times ranked

2082
citing authors

#	ARTICLE	IF	CITATIONS
1	Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 23-37.	2.0	4
2	The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. <i>International Journal of Cancer</i> , 2021, 148, 2640-2651.	2.3	90
3	Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1705-1719.	2.0	96
4	Regulation of PD-L1 expression in the tumor microenvironment. <i>Journal of Hematology and Oncology</i> , 2021, 14, 10.	6.9	281
5	ASO Author Reflections: Impact of Ipsilateral Supraclavicular Lymph Node Dissection on Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 5110-5111.	0.7	0
6	Impact of Ipsilateral Supraclavicular Lymph Node Dissection (ISLND) for Breast Cancer Patients and a Nomogram for Predicting Ipsilateral Supraclavicular Pathological Complete Response (ispCR). <i>Annals of Surgical Oncology</i> , 2021, 28, 5098-5109.	0.7	7
7	Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. <i>Experimental Hematology and Oncology</i> , 2021, 10, 18.	2.0	64
8	Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 9085-9093.	0.9	4
9	The role of cancer-derived microRNAs in cancer immune escape. <i>Journal of Hematology and Oncology</i> , 2020, 13, 25.	6.9	145
10	The roles of exosomes in cancer drug resistance and its therapeutic application. <i>Clinical and Translational Medicine</i> , 2020, 10, e257.	1.7	47
11	Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. <i>Molecular Cancer</i> , 2019, 18, 155.	7.9	723
12	LncRNA SNHG7 contributes to tumorigenesis and progression in breast cancer by interacting with miR-34a through EMT initiation and the Notch-1 pathway. <i>European Journal of Pharmacology</i> , 2019, 856, 172407.	1.7	65